Department of Nutrition and Integrative Physiology, College of Health, University of Utah, Salt Lake City, UT, USA.
Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Curr Med Chem. 2024;31(22):3345-3359. doi: 10.2174/0929867330666230622114235.
Cell-free circulating DNA has been known for many years, but this knowledge has not been beneficial for diagnosis. In this meta-analysis, we examine the diagnostic role of circulating cell-free DNA in HCC patients to find a reliable biomarker for the early detection of HCC.
We performed a systematic literature search using Science Direct, Web of Science, PubMed/Medline, Scopus, Google Scholar, and Embase, up to April 1st, 2022. Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software calculated the pooled specificity, sensitivity, area under the curve (AUC), diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR) Q*index, and summary receiver-- operating characteristic (SROC) for the role of cfDNA as a biomarker for HCC patients. Moreover, the subgroup analyses have been performed based on sample types (serum/plasma) and detection methods (MS-PCR/methylation).
A total of 7 articles (9 studies) included 697 participants (485 cases and 212 controls). The overall pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were 0.706 (95% CI: 0.671 - 0.739), 0.905 (95% CI: 0.865 - 0.937), 6.66 (95% CI: 4.36 - 10.18), 0.287 (95% CI: 0.185 - 0.445), 28.40 (95% CI: 13.01 - 62.0), and 0.93, respectively. We conducted a subgroup analysis of diagnostic value, which showed that the plasma sample had a better diagnostic value compared to the serum.
This meta-analysis showed that cfDNA could be a fair biomarker for diagnosing HCC patients.
无细胞循环 DNA 多年来已为人所知，但这些知识对诊断并没有益处。在这项荟萃分析中，我们检查了循环无细胞 DNA 在 HCC 患者中的诊断作用，以寻找 HCC 早期检测的可靠生物标志物。
我们使用 Science Direct、Web of Science、PubMed/Medline、Scopus、Google Scholar 和 Embase 进行了系统的文献检索，检索时间截至 2022 年 4 月 1 日。Meta-Disc V.1.4 和 Comprehensive Meta-Analysis V.3.3 软件计算了 cfDNA 作为 HCC 患者生物标志物的 pooled 特异性、敏感性、曲线下面积（AUC）、诊断比值比（DOR）、阳性似然比（PLR）、阴性似然比（NLR）Q*指数和汇总受试者工作特征（SROC）。此外，还根据样本类型（血清/血浆）和检测方法（MS-PCR/甲基化）进行了亚组分析。
共有 7 篇文章（9 项研究）纳入了 697 名参与者（485 例病例和 212 例对照）。总的 pooled 敏感性、特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）和曲线下面积（AUC）分别为 0.706（95%CI：0.671-0.739）、0.905（95%CI：0.865-0.937）、6.66（95%CI：4.36-10.18）、0.287（95%CI：0.185-0.445）、28.40（95%CI：13.01-62.0）和 0.93。我们进行了诊断价值的亚组分析，结果表明，与血清相比，血浆样本具有更好的诊断价值。
这项荟萃分析表明，cfDNA 可能是诊断 HCC 患者的一种合理的生物标志物。
